The immune response to SARS-CoV-2 in people with HIV

MA Höft, WA Burgers, C Riou - Cellular & molecular immunology, 2024 - nature.com
This review examines the intersection of the HIV and SARS-CoV-2 pandemics. People with
HIV (PWH) are a heterogeneous group that differ in their degree of immune suppression …

HIV infection

SG Deeks, J Overbaugh, A Phillips… - Nature reviews Disease …, 2015 - nature.com
More than 75 million people worldwide have been infected with human immunodeficiency
virus (HIV), and there are now approximately 37 million individuals living with the infection …

Immune activation and HIV persistence: implications for curative approaches to HIV infection

NR Klatt, N Chomont, DC Douek… - Immunological …, 2013 - Wiley Online Library
Despite complete or near‐complete suppression of human immunodeficiency virus (HIV)
replication with combination antiretroviral therapy, both HIV and chronic …

Effect of early versus deferred antiretroviral therapy for HIV on survival

MM Kitahata, SJ Gange, AG Abraham… - … England Journal of …, 2009 - Mass Medical Soc
Background The optimal time for the initiation of antiretroviral therapy for asymptomatic
patients with human immunodeficiency virus (HIV) infection is uncertain. Methods We …

Pathogenic mechanisms of HIV disease

S Moir, TW Chun, AS Fauci - Annual review of pathology …, 2011 - annualreviews.org
Human immunodeficiency virus (HIV) infection is generally characterized by inefficient viral
transmission; an acute phase of intense viral replication and dissemination to lymphoid …

Antiretroviral therapy and management of HIV infection

PA Volberding, SG Deeks - The Lancet, 2010 - thelancet.com
Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic
disease. There are now 17 drugs in common use for HIV treatment. Patients who can access …

Residual immune dysregulation syndrome in treated HIV infection

MM Lederman, NT Funderburg, RP Sekaly… - Advances in …, 2013 - Elsevier
Antiretroviral therapy has revolutionized the course of HIV infection, improving immune
function and decreasing dramatically the mortality and morbidity due to the opportunistic …

Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy

PW Hunt, JN Martin, E Sinclair, L Epling… - Journal of Infectious …, 2011 - academic.oup.com
Background. Elevated immune activation persists during treated human immunodeficiency
virus (HIV) infection and is associated with blunted CD4 recovery and premature mortality …

Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells

H Hatano, V Jain, PW Hunt, TH Lee… - The Journal of …, 2013 - academic.oup.com
Background. Studies aimed at defining the association between host immune responses
and human immunodeficiency virus (HIV) persistence during therapy are necessary to …

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts

L Hocqueloux, V Avettand-Fenoël… - Journal of …, 2013 - academic.oup.com
Objectives To characterize viro-immunological outcomes following long-term combined
antiretroviral therapy (cART) initiated during primary HIV infection (PHI) or chronic HIV …